Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Late clinical outcome of stent trials: a matter of life or death?

Millions of patients with obstructive coronary artery disease worldwide are treated with metallic stents each year. Since the first stent implantation in a human in 1986, stents have undergone substantial refinements that have involved numerous innovations and extensive clinical research.1 Over three decades, various problems were faced and solved or minimised. Among them were the frequent acute and sub-acute thrombotic occlusions of the very first stents, the recurrence of difficult-to-treat lesions within bare metal stents (typically within the first 6 months after implantation), and the late (1–12 months after implantation) and very late (>1 year after implantation) formation of thrombi in the first generation of drug-eluting stents.